BG107774A - Combination of gaba agonists and sorbitol dehydrogenase inhibitors - Google Patents

Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Info

Publication number
BG107774A
BG107774A BG107774A BG10777403A BG107774A BG 107774 A BG107774 A BG 107774A BG 107774 A BG107774 A BG 107774A BG 10777403 A BG10777403 A BG 10777403A BG 107774 A BG107774 A BG 107774A
Authority
BG
Bulgaria
Prior art keywords
diabetic
prodrug
combinations
combination
gaba agonists
Prior art date
Application number
BG107774A
Other languages
Bulgarian (bg)
English (en)
Inventor
Banavara L. Mylari
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107774A publication Critical patent/BG107774A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG107774A 2000-11-30 2003-05-07 Combination of gaba agonists and sorbitol dehydrogenase inhibitors BG107774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30
PCT/IB2001/002213 WO2002043762A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
BG107774A true BG107774A (en) 2004-01-30

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107774A BG107774A (en) 2000-11-30 2003-05-07 Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Country Status (38)

Country Link
US (1) US6544998B2 (cs)
EP (1) EP1337271B1 (cs)
JP (1) JP2004514699A (cs)
KR (1) KR20030059290A (cs)
CN (1) CN1477975A (cs)
AP (1) AP2001002360A0 (cs)
AR (1) AR031431A1 (cs)
AT (1) ATE281181T1 (cs)
AU (1) AU2002215159A1 (cs)
BG (1) BG107774A (cs)
BR (1) BR0115783A (cs)
CA (1) CA2430298A1 (cs)
CR (1) CR6964A (cs)
CZ (1) CZ20031399A3 (cs)
DE (1) DE60106968T2 (cs)
DO (1) DOP2001000289A (cs)
EA (1) EA200300432A1 (cs)
EC (1) ECSP034624A (cs)
EE (1) EE200300248A (cs)
ES (1) ES2230378T3 (cs)
HR (1) HRP20030420A2 (cs)
HU (1) HUP0302160A3 (cs)
IL (1) IL155704A0 (cs)
IS (1) IS6786A (cs)
MA (1) MA26964A1 (cs)
MX (1) MXPA03004870A (cs)
NO (1) NO20032441L (cs)
OA (1) OA12534A (cs)
PA (1) PA8534101A1 (cs)
PE (1) PE20020597A1 (cs)
PL (1) PL365927A1 (cs)
PT (1) PT1337271E (cs)
SK (1) SK6192003A3 (cs)
SV (1) SV2003000751A (cs)
TN (1) TNSN01169A1 (cs)
UY (1) UY27042A1 (cs)
WO (1) WO2002043762A2 (cs)
ZA (1) ZA200303381B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
BR0209973A (pt) * 2001-05-25 2004-04-06 Warner Lambert Co Composição farmacêutica lìquida
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
BRPI0509399A (pt) * 2004-04-02 2007-09-18 Impax Laboratories Inc forma de dosagem farmacêutica
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
EP2604599A1 (en) 2007-04-27 2013-06-19 Purdue Pharma LP TRPV1 antagonists and uses thereof
EP2207569B1 (en) * 2007-10-09 2013-03-27 Merck Patent GmbH Pharmaceutical compositions containing benfotiamine and one or more pharmaceutically active agents for the treatment of pain conditions of neuropathic origin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
EP3753410A3 (en) * 2010-09-28 2021-04-28 The Regents Of The University Of California Combinations comprising gaba agonists in treatment of hyperglycemia
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
CN113966396A (zh) * 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
EP0021121B1 (en) 1979-06-01 1983-05-11 The Wellcome Foundation Limited 1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
NZ254550A (en) * 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
WO2000050034A1 (en) * 1999-02-24 2000-08-31 The Regents Of The University Of California Gaba receptors mediate inhibition of t cell responses
ES2215570T3 (es) * 1999-04-01 2004-10-16 Pfizer Products Inc. Compuestos para tratar y prevenir complicaciones diabeticas.
CA2366858A1 (en) * 1999-04-01 2000-10-12 Margaret Yuhua Chu-Moyer Sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
DE60106968D1 (de) 2004-12-09
JP2004514699A (ja) 2004-05-20
HUP0302160A2 (hu) 2003-11-28
ECSP034624A (es) 2003-07-25
SV2003000751A (es) 2003-01-13
UY27042A1 (es) 2002-07-31
IL155704A0 (en) 2003-11-23
AU2002215159A1 (en) 2002-06-11
WO2002043762A2 (en) 2002-06-06
SK6192003A3 (en) 2004-07-07
AP2001002360A0 (en) 2001-12-31
MA26964A1 (fr) 2004-12-20
ZA200303381B (en) 2004-04-30
CR6964A (es) 2004-02-02
US6544998B2 (en) 2003-04-08
PA8534101A1 (es) 2002-10-31
DOP2001000289A (es) 2003-02-15
TNSN01169A1 (fr) 2005-11-10
ATE281181T1 (de) 2004-11-15
PE20020597A1 (es) 2002-07-08
PL365927A1 (en) 2005-01-10
BR0115783A (pt) 2003-09-16
EP1337271B1 (en) 2004-11-03
HUP0302160A3 (en) 2005-05-30
ES2230378T3 (es) 2005-05-01
NO20032441L (no) 2003-07-03
PT1337271E (pt) 2005-01-31
HRP20030420A2 (en) 2004-08-31
EE200300248A (et) 2003-10-15
MXPA03004870A (es) 2003-08-19
IS6786A (is) 2003-04-14
US20020091128A1 (en) 2002-07-11
WO2002043762A3 (en) 2003-03-13
CZ20031399A3 (cs) 2004-04-14
AR031431A1 (es) 2003-09-24
DE60106968T2 (de) 2005-11-03
CN1477975A (zh) 2004-02-25
EP1337271A2 (en) 2003-08-27
CA2430298A1 (en) 2002-06-06
NO20032441D0 (no) 2003-05-28
EA200300432A1 (ru) 2003-10-30
OA12534A (en) 2006-06-05
KR20030059290A (ko) 2003-07-07

Similar Documents

Publication Publication Date Title
AP2001002360A0 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors.
AP2001002359A0 (en) Combination of gaba agonists and aldose reductase inhibitors.
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
BRPI0809011A8 (pt) composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
ATE440603T1 (de) 8-hydroxychinolinderivate
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
EP1106210A3 (en) Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
EP1022026A3 (en) Pharmaceutical compositions for treating nitrate-induced tolerance
MXPA05009303A (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
BR0002953A (pt) Composições e tratamento para complicações diabéticas
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
SE0102055D0 (sv) New Compounds
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
AU2003250701A1 (en) Protein tyrosine kinase inhibitors
EP1106184A3 (en) Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
WO2005113012A3 (en) Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
HRP20041150A2 (en) Method for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women
WO2008079728A3 (en) Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
WO2002032411A3 (en) Combination of statins and sorbitol dehydrogenase inhibitors